Spending the cost of Bortezomib ACTe launch for the first injection of patients in need.

October 20, 2020

Author: Acteropharma

Considering the current situation in the country and taking into account the needs of patients, Actero Company decided to spend all the costs related to the unveiling of the drug Bortezomib ACTe on the first free injection of patients’ candidates receiving Bortezomib. Therefore, by delivering the drug sample to physicians specializing in this field, treatment coverage began in a number of eligible patients.

Last News

Actero Support in Congress 1400

Site
July 24, 2022

Author:

Acteropharma
Actero company’s social respomsibility of patient support in Hematology-Oncology Congress and Radiation Therapy Congress

Best of ASCO 2021

Dr-noroozi-event-2048x1367
November 16, 2021

Author:

Acteropharma
The aforesaid seminar has been held for the first time in Iran with the hospitality of Isfahan city, with the cooperation of Radiation-Oncologists from all over of the country and Actero Pharma.

“Uro-Oncology Tumor board: Challenges of Prostate Cancer Treatment” (Semi-Virtual)

Dr-noroozi-event-2048x1367
November 16, 2021

Author:

Acteropharma
Uro-Oncology research Center of Tehran University of Medical science, in cooperation with Actero Pharma has held a semi-virtual tumor board.